
Celgene has shelled out $300 million upfront, with a potential further $475 million in milestone payments, for Delinia, an autoimmune …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

